Carmot Therapeutics Status
The company raised $15 million of Series B venture funding in a deal co-led by Horizons Ventures and The Column Group on January 17, 2018, putting the pre-money valuation at $47.2 million. Jerome Dahan and other undisclosed investors also participated in the round. The company intends to use the funds to support development of their lead type 2 diabetes drug through early clinical proof of concept and expansion of their efforts targeting de-ubiquitinating enzymes.
Leave a Reply ·
You must be logged in to post a comment.